SG11201906192SA - Methods of treating cancer with anti-pd-1 antibodies - Google Patents

Methods of treating cancer with anti-pd-1 antibodies

Info

Publication number
SG11201906192SA
SG11201906192SA SG11201906192SA SG11201906192SA SG11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA
Authority
SG
Singapore
Prior art keywords
international
tesaro
waltham
suite
street north
Prior art date
Application number
SG11201906192SA
Inventor
David Jenkins
Haley Laken
Ellie Im
Allene Diaz
Sharon Lu
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of SG11201906192SA publication Critical patent/SG11201906192SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 July 2018 (12.07.2018) WIP0 1 PCT Ilium omit Oil Oil mum ono mom oimIE (10) International Publication Number WO 2018/129559 Al (51) International Patent Classification: CO7K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/013029 (22) International Filing Date: 09 January 2018 (09.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/444,336 09 January 2017 (09.01.2017) US 62/477,423 27 March 2017 (27.03.2017) US 62/491,220 27 April 2017 (27.04.2017) US 62/556,386 09 September 2017 (09.09.2017) US (71) Applicant: TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). (72) Inventors: JENKINS, David; c/o Tesaro, Inc., 1000 Win- ter Street North, Suite 3300, Waltham, MA 02451 (US). LAKEN, Haley; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). IM, Ellie; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). DIAZ, Allene; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). LU, Sharon; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). (74) Agent: ESPINO, Christine, G. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 O \" (57) : The present invention provides methods of administering certain PD-1 binding agents to patients having cancer. Dosage 0 regimens for compositions comprising a PD-1 binding agent are also explicitly provided. (54) Title: METHODS OF TREATING CANCER WITH ANTI-PD-1 ANTIBODIES
SG11201906192SA 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies SG11201906192SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762444336P 2017-01-09 2017-01-09
US201762477423P 2017-03-27 2017-03-27
US201762491220P 2017-04-27 2017-04-27
US201762556386P 2017-09-09 2017-09-09
PCT/US2018/013029 WO2018129559A1 (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
SG11201906192SA true SG11201906192SA (en) 2019-08-27

Family

ID=61188903

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906192SA SG11201906192SA (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies
SG10201913075RA SG10201913075RA (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913075RA SG10201913075RA (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies

Country Status (21)

Country Link
US (2) US11407830B2 (en)
EP (2) EP4219563A3 (en)
JP (2) JP7110206B6 (en)
KR (1) KR102606252B1 (en)
CN (1) CN110382545A (en)
AU (1) AU2018206481A1 (en)
BR (1) BR112019014187A2 (en)
CA (1) CA3049440A1 (en)
DK (1) DK3565844T3 (en)
ES (1) ES2945745T3 (en)
FI (1) FI3565844T3 (en)
HU (1) HUE061842T2 (en)
IL (1) IL267804A (en)
MA (1) MA47208A (en)
MX (1) MX2019008207A (en)
PL (1) PL3565844T3 (en)
PT (1) PT3565844T (en)
SG (2) SG11201906192SA (en)
TW (1) TWI767976B (en)
WO (1) WO2018129559A1 (en)
ZA (1) ZA201904316B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP3526256A1 (en) 2016-10-11 2019-08-21 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
KR20190101364A (en) * 2016-11-01 2019-08-30 테사로, 인코포레이티드 Antibody Against Probable Death-1 (PD-1)
ES2945745T3 (en) 2017-01-09 2023-07-06 Tesaro Inc Methods of treating cancers with anti-PD-1 antibodies
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
MX2020003770A (en) 2017-09-30 2020-07-29 Tesaro Inc Combination therapies for treating cancer.
CN111182923A (en) 2017-10-06 2020-05-19 特沙诺有限公司 Combination therapy and uses thereof
TW202024638A (en) * 2018-09-04 2020-07-01 美商泰沙羅公司 Methods of treating cancer
CN113330007A (en) 2018-10-03 2021-08-31 特沙诺有限公司 Crystalline forms of nilapali free base
EP3860981B1 (en) 2018-10-03 2023-11-29 Tesaro, Inc. Niraparib salts
WO2020128908A2 (en) * 2018-12-20 2020-06-25 Medimmune, Llc Methods for selection and expansion of t cells expressing pd-1
SG11202112733XA (en) * 2019-05-31 2021-12-30 Alx Oncology Inc Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
KR20220129548A (en) 2019-12-18 2022-09-23 테사로, 인코포레이티드 Biopharmaceutical compositions and related methods
CN113116881A (en) * 2019-12-31 2021-07-16 甫康（上海）健康科技有限责任公司 Pharmaceutical composition for treating tumors and application thereof
BR112022014562A2 (en) 2020-01-28 2022-09-13 Glaxosmithkline Ip Dev Ltd COMBINATION TREATMENTS, USES AND METHODS THEREOF
WO2021167177A1 (en) * 2020-02-18 2021-08-26 주식회사 이노베이션바이오 Companion diagnosis biomarker composition and companion diagnosis kit containing same
MX2022015881A (en) * 2020-06-18 2023-01-24 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists.
WO2022025482A1 (en) * 2020-07-29 2022-02-03 재단법인 아산사회복지재단 Composition for preventing and treating colorectal cancer, comprising streptonigrin and immune checkpoint inhibitor as active ingredients
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
WO2023153763A1 (en) * 2022-02-08 2023-08-17 고려대학교 산학협력단 Cancer vaccine comprising epitope of c-met and epitope of hif1alpha, and use thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DK0557459T3 (en) 1990-11-13 1997-12-15 Immunex Corp Bifunctional, selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CA2414331C (en) 2000-06-28 2011-11-29 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
FR2814642B1 (en) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER
JP3871326B2 (en) 2000-11-15 2007-01-24 小野薬品工業株式会社 PD-1-deficient mice and uses thereof
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
BR0208637A (en) 2001-04-02 2004-12-07 Wyeth Corp Pd-1, a b7-4 receptor, and uses thereof
US20040241745A1 (en) 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
JP4488740B2 (en) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Agents that modulate immune cell activation and methods of use thereof
SI2206517T1 (en) 2002-07-03 2023-12-29 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
KR101339628B1 (en) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101514463B1 (en) 2005-06-08 2015-04-28 다나-파버 캔서 인스티튜트 인크. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
SI2074145T1 (en) * 2006-10-02 2017-12-29 Ac Immune S.A. Humanized antibody against amyloid beta
NZ596237A (en) 2006-12-27 2012-07-27 Dana Farber Cancer Inst Inc Compositions and methods for the treatment of infections and tumors
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
BRPI0807952A2 (en) 2007-02-20 2014-06-10 Anaptysbio Inc Somatic Hypermutation Systems
JP2010524846A (en) 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー Anti-sclerostin antibody
EP2162472B1 (en) 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
KR101653548B1 (en) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-4-3--3--2--7- Pharmaceutically acceptable salts of 2-4-3-piperidin-3-ylphenyl-2H-indazole-7-carboxamide
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010001617A1 (en) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
JP2012501670A (en) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド PD-1-specific antibodies and uses thereof
MX2011003195A (en) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
KR101050829B1 (en) 2008-10-02 2011-07-20 서울대학교산학협력단 Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
DK2370593T3 (en) 2008-11-28 2016-07-04 Univ Emory A method for determining the effect of PD-1 Antagonists
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
BR112012010707B1 (en) * 2009-11-04 2022-08-30 Merck Sharp & Dohme Corp ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, COMPOSITION, AND, USE OF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
AU2010343056A1 (en) 2009-12-29 2012-08-02 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20130035472A1 (en) 2010-03-17 2013-02-07 Anaptysbio, Inc. Method of producing transcripts using cryptic splice sites
US20110256135A1 (en) * 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
US20130217656A1 (en) 2010-08-12 2013-08-22 Beth Israel Deaconess Medical Center Inc Methods and compositions for diagnosing and treating lupus
US20130310266A1 (en) 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
US9029315B2 (en) 2010-11-11 2015-05-12 The University Of Hong Kong Soluble PD-1 variants, fusion constructs, and uses thereof
CN110038135B (en) 2011-03-17 2021-03-05 伯明翰大学 Redirected immunotherapy
KR20190116563A (en) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN107519486B (en) 2011-06-24 2021-06-11 台北荣民总医院 Method for enhancing immune response in the treatment of infectious and malignant diseases
EP2742953B1 (en) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150079192A1 (en) 2012-05-21 2015-03-19 Marv Enterprises, LLC Treatment of cancer by manipulating the immune system
WO2013174997A1 (en) 2012-05-25 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
CA2874144C (en) 2012-05-31 2023-12-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9815897B2 (en) * 2013-05-02 2017-11-14 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
EP3114144A1 (en) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
TWI697500B (en) 2014-03-14 2020-07-01 瑞士商諾華公司 Antibody molecules to lag-3 and uses thereof
EP3590967A1 (en) 2014-03-24 2020-01-08 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist properties and use thereof
LT3157956T (en) 2014-06-19 2020-05-11 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
CN107074947B (en) 2014-08-05 2021-04-09 马布奎斯特公司 Immunity agent binding to PD-1
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
ES2774448T3 (en) 2014-10-03 2020-07-21 Novartis Ag Combination therapies
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
MA41218A (en) 2014-12-19 2017-10-24 Advaxis Inc LISTERIA VACCINE COMBINATION WITH ANTI-OX40 OR ANTI-GITR ANTIBODIES
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
LT3240801T (en) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
CA3081058C (en) 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
MA41463A (en) 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
EP3283107B1 (en) * 2015-04-17 2020-05-27 Bristol-Myers Squibb Company Compositions comprising a combination of ipilimumab and nivolumab
KR20170140316A (en) 2015-04-28 2017-12-20 브리스톨-마이어스 스큅 컴퍼니 Treatment of PD-L1-positive melanoma with anti-PD-1 antibody
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3478286B1 (en) 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
KR20190101364A (en) * 2016-11-01 2019-08-30 테사로, 인코포레이티드 Antibody Against Probable Death-1 (PD-1)
EA201990741A1 (en) 2016-11-29 2019-11-29 ANTIBODIES AIMED AGAINST PROTEIN-1 PROGRAMMED DEATH (PD-1)
ES2945745T3 (en) 2017-01-09 2023-07-06 Tesaro Inc Methods of treating cancers with anti-PD-1 antibodies
AU2018205401A1 (en) 2017-01-09 2019-07-25 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
MX2020003770A (en) 2017-09-30 2020-07-29 Tesaro Inc Combination therapies for treating cancer.

Also Published As

Publication number Publication date
US20200239574A1 (en) 2020-07-30
HUE061842T2 (en) 2023-08-28
KR102606252B1 (en) 2023-11-23
EP3565844B1 (en) 2023-03-01
EP3565844B8 (en) 2023-04-12
MX2019008207A (en) 2019-12-11
TWI767976B (en) 2022-06-21
PT3565844T (en) 2023-05-02
MA47208A (en) 2019-11-13
EP4219563A2 (en) 2023-08-02
WO2018129559A1 (en) 2018-07-12
JP7110206B6 (en) 2022-08-25
US11407830B2 (en) 2022-08-09
JP2022082809A (en) 2022-06-02
KR20190114996A (en) 2019-10-10
DK3565844T3 (en) 2023-05-01
ES2945745T3 (en) 2023-07-06
AU2018206481A1 (en) 2019-07-25
US20230111418A1 (en) 2023-04-13
CN110382545A (en) 2019-10-25
EP4219563A3 (en) 2023-10-04
JP7110206B2 (en) 2022-08-01
TW201831200A (en) 2018-09-01
IL267804A (en) 2019-09-26
PL3565844T3 (en) 2023-06-12
EP3565844A1 (en) 2019-11-13
SG10201913075RA (en) 2020-02-27
BR112019014187A2 (en) 2020-02-11
CA3049440A1 (en) 2018-07-12
ZA201904316B (en) 2022-12-21
FI3565844T3 (en) 2023-05-09
JP2020504141A (en) 2020-02-06

Similar Documents

Publication Publication Date Title
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201811432WA (en) Rna for cancer therapy
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201808990QA (en) Compositions for topical application of compounds
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201909011PA (en) Niraparib compositions
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201809751XA (en) Egfr inhibitor compounds
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization